1. Effects of Daltroban, a Thromboxane (TX) A2 Receptor Antagonist, on Lipid Metabolism and Atherosclerosis
- Author
-
J. Metz, F. Hartig, K. Stegmeier, and Johannes Pill
- Subjects
Cholesterol ,Thromboxane ,medicine.drug_class ,Lipid metabolism ,Pharmacology ,Receptor antagonist ,Thromboxane receptor ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,Hepatocyte ,medicine ,lipids (amino acids, peptides, and proteins) ,Antagonism ,Receptor - Abstract
In rat hepatocyte cultures daltroban reduced 14C-acetate incorporation stronger into cholesterol (CH) esters than into free CH. Further data suggest that the reduction of cellular sterols by daltroban is independent from its TXA2 receptor antagonistic activity and caused by reduced capacity of ACAT depending CH esterification. In rabbits fed CH-enriched diet treatment with daltroban led to an inhibition of platelet aggregation and to a significant reduction of progression of atherosclerosis. Both reduced CH esterification and TXA2 receptor antagonism may contribute to the diminution of progression of atherosclerosis by daltroban.
- Published
- 1992
- Full Text
- View/download PDF